1
|
Talbot B, Cass A, Walker R, Hooi L, Jardine M, Jun M, Rogers K, Sukkar L, Smyth B, Gallagher M. Comparing survival in patients with chronic kidney disease across three countries - Results from the study of heart and renal protection-extended review. Nephrology (Carlton) 2023; 28:36-43. [PMID: 36309984 PMCID: PMC10946510 DOI: 10.1111/nep.14127] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2022] [Revised: 10/05/2022] [Accepted: 10/26/2022] [Indexed: 11/29/2022]
Abstract
AIM This study examined whether survival and causes of death differed between participants enrolled from Australia (AUS), Malaysia (MYL), and New Zealand (NZ) in extended follow-up of the Study of Heart and Renal Protection (SHARP), a randomized controlled trial (RCT) of participants with moderate to severe chronic kidney disease comparing placebo to combination therapy with Simvastatin and Ezetimibe. METHODS All participants alive at final SHARP study visit in participating centres were eligible for inclusion. Consenting participants were re-enrolled following final SHARP Study visit and followed for 5 years. Data collection included: significant medical events, hospital admissions and requirement for kidney replacement therapy. Data linkage was performed to national kidney and mortality registries. The primary outcome was all-cause mortality compared across the three countries. RESULTS The SHARP trial randomized 2029 participants from AUS (1043/2029, 51%), MYL (701/2029, 35%), and NZ (285/2029, 14%), with 1136 participants alive and eligible for extended follow-up at the end of SHARP. In multivariable analysis, risk of death was increased for participants in MYL (HR 1.37, 95% CI 1.17-1.61, p < .001) and NZ (HR 1.28, 95% CI 1.04-1.57, p = .02) when compared to AUS participants. Adjustment for kidney transplantation as a competing risk did not explain the variation seen between countries. CONCLUSION This study allows a better understanding of the differences in long-term mortality risk across participants from AUS, MYL, and NZ in extended follow-up of the SHARP study and demonstrates the feasibility and value of extended follow-up of participants enrolled in RCTs.
Collapse
Affiliation(s)
- Benjamin Talbot
- The George Institute for Global HealthThe University of New South WalesSydneyNew South WalesAustralia
- Ellen Medical DevicesSydneyNew South WalesAustralia
| | - Alan Cass
- Menzies School of Health ResearchCharles Darwin UniversityDarwinNorthern TerritoryAustralia
| | - Robert Walker
- Dunedin School of MedicineUniversity of OtagoDunedinOtagoNew Zealand
| | - Lai Hooi
- Sultanah Aminah HospitalJohor BahruJohorMalaysia
| | - Meg Jardine
- The George Institute for Global HealthThe University of New South WalesSydneyNew South WalesAustralia
- NHMRC Clinical Trial CentreThe University of SydneySydneyNew South WalesAustralia
- Concord Repatriation General HospitalSydneyNew South WalesAustralia
| | - Min Jun
- The George Institute for Global HealthThe University of New South WalesSydneyNew South WalesAustralia
| | - Kris Rogers
- The George Institute for Global HealthThe University of New South WalesSydneyNew South WalesAustralia
- Faculty of HealthUniversity of Technology SydneySydneyNew South WalesAustralia
| | - Louisa Sukkar
- The George Institute for Global HealthThe University of New South WalesSydneyNew South WalesAustralia
- Sydney School of Public HealthThe University of SydneySydneyNew South WalesAustralia
| | - Brendan Smyth
- The George Institute for Global HealthThe University of New South WalesSydneyNew South WalesAustralia
- NHMRC Clinical Trial CentreThe University of SydneySydneyNew South WalesAustralia
- Department of Renal MedicineSt George HospitalSydneyNew South WalesAustralia
| | - Martin Gallagher
- The George Institute for Global HealthThe University of New South WalesSydneyNew South WalesAustralia
- South Western Sydney Clinical SchoolUniversity of New South WalesSydneyNew South WalesAustralia
| |
Collapse
|
2
|
Campain A, Hockham C, Sukkar L, Rogers K, Chow CK, Lung T, Jun M, Pollock C, Cass A, Sullivan D, Comino E, Peiris D, Jardine M. Prior Cardiovascular Treatments-A Key Characteristic in Determining Medication Adherence After an Acute Myocardial Infarction. Front Pharmacol 2022; 13:834898. [PMID: 35330840 PMCID: PMC8940291 DOI: 10.3389/fphar.2022.834898] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2021] [Accepted: 02/15/2022] [Indexed: 11/30/2022] Open
Abstract
Objective: To investigate long-term adherence to guideline-recommended cardioprotective medications following hospitalization for an acute myocardial infarction (AMI), and identify characteristics associated with adherence. Methods: An Australian population-based cohort study was used to identify participants who had their first AMI between 2006 and 2014 and were alive after 12 months. Linked routinely collected hospital, and prescription medication claims data was used to study adherence over time. Predictors and rates of adherence to both lipid-lowering medication and renin-angiotensin system blockade at 12 months post-AMI was assessed. Results: 14,200 people (mean age 69.9 years, 38.7% female) were included in our analysis. At 12 months post-AMI, 29.5% (95% CI: 28.8–30.3%) of people were adherent to both classes of medication. Individuals receiving treatment with both lipid-lowering medication and renin-angiotensin system blockade during the 6 months prior to their AMI were over 9 times more likely to be adherent to both medications at 12 months post-AMI (66.2% 95% CI: 64.8–67.5%) compared to those with no prior medication use (treatment naïve) (7.1%, 95% CI: 6.4–7.9%). Prior cardiovascular treatment was the strongest predictor of long-term adherence even after adjusting for age, sex, education and income. Conclusions: Despite efforts to improve long-term medication adherence in patients who have experienced an acute coronary event, considerable gaps remain. Of particular concern are people who are commencing guideline-recommended cardioprotective medication at the time of their AMI. The relationship between prior cardiovascular treatments and post AMI adherence offers insight into the support needs for the patient. Health care intervention strategies, strengthened by enabling policies, are needed to provide support to patients through the initial months following their AMI.
Collapse
Affiliation(s)
- Anna Campain
- The George Institute for Global Heath, UNSW, Sydney, NSW, Australia.,Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia
| | - Carinna Hockham
- School of Public Health, Imperial College London, The George Institute for Global Health, London, United Kingdom
| | - Louisa Sukkar
- The George Institute for Global Heath, UNSW, Sydney, NSW, Australia.,Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia
| | - Kris Rogers
- The George Institute for Global Heath, UNSW, Sydney, NSW, Australia.,Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia.,Graduate School of Health, University of Technology Sydney, Sydney, NSW, Australia
| | - Clara K Chow
- The George Institute for Global Heath, UNSW, Sydney, NSW, Australia.,Westmead Applied Research Centre, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.,Department of Cardiology, Westmead Hospital, Sydney, NSW, Australia
| | - Thomas Lung
- The George Institute for Global Heath, UNSW, Sydney, NSW, Australia.,Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia.,Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia
| | - Min Jun
- The George Institute for Global Heath, UNSW, Sydney, NSW, Australia.,Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia
| | - Carol Pollock
- Renal Division, Kolling Institute for Medical Research, Sydney, NSW, Australia.,University of Sydney, Sydney, NSW, Australia
| | - Alan Cass
- Menzies School of Health Research, Charles Darwin University, Darwin, NT, Australia
| | - David Sullivan
- Department of Chemical Pathology Royal Prince Alfred Hospital, Camperdown, NSW, Australia.,NSW Health Pathology, Newcastle, NSW, Australia.,Central Clinical School, University of Sydney, Camperdown, NSW, Australia
| | - Elizabeth Comino
- Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia
| | - David Peiris
- The George Institute for Global Heath, UNSW, Sydney, NSW, Australia.,Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia
| | - Meg Jardine
- Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.,NHMRC Clinical Trials Centre, The University of Sydney, Sydney, NSW, Australia.,Concord Repatriation General Hospital, Sydney, NSW, Australia
| |
Collapse
|
3
|
Zhang H, Rogers K, Sukkar L, Jun M, Kang A, Young T, Campain A, Cass A, Chow CK, Comino E, Foote C, Gallagher M, Knight J, Liu B, Lung T, McNamara M, Peiris D, Pollock C, Sullivan D, Wong G, Zoungas S, Jardine M, Hockham C. Prevalence, incidence and risk factors of diabetes in Australian adults aged ≥45 years: A cohort study using linked routinely-collected data. J Clin Transl Endocrinol 2020; 22:100240. [PMID: 33294382 PMCID: PMC7691170 DOI: 10.1016/j.jcte.2020.100240] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/06/2020] [Revised: 09/12/2020] [Accepted: 11/04/2020] [Indexed: 01/03/2023]
Abstract
Aims To use linked routinely-collected health data to estimate diabetes prevalence and incidence in an Australian cohort of adults aged ≥45 years, and examine risk factors associated with incident disease. Research design and methods The EXamining ouTcomEs in chroNic Disease in the 45 and Up Study (EXTEND45) Study is a linked data study that combines baseline questionnaire responses from the population-based 45 and Up Study (2006–2009, n = 267,153) with multiple routinely-collected health databases up to December 2014. Among participants with ≥1 linked result for any laboratory test, diabetes status was determined from multiple data sources according to standard biochemical criteria, use of glucose-lowering medication or self-report, and the prevalence and incidence rate calculated. Independent risk factors of incident diabetes were examined using multivariable Cox regression. Results Among 152,169 45 and Up Study participants with ≥1 linked laboratory result in the EXTEND45 database (mean age 63.0 years; 54.9% female), diabetes prevalence was 10.8% (95% confidence interval [CI] 10.6%–10.9%). Incident disease in those without diabetes at baseline (n = 135,810; mean age 62.5 years; 56.1% female) was 10.0 per 1,000 person-years (95% CI 9.8–10.2). In all age groups, diabetes incidence was lower in women compared to men, an association that persisted in the fully adjusted analyses. Other independent risk factors of diabetes were older age, being born outside of Australia (with the highest rate of 19.2 per 1,000 person-years observed in people born in South and Central Asia), lower education status, lower annual household income, residence in a major city, family history of diabetes, personal history of cardiovascular disease or hypertension, higher body mass index, smoking and long sleeping hours. Conclusions Our study represents an efficient approach to assessing diabetes frequency and its risk factors in the community. The infrastructure provided by the EXTEND45 Study will be useful for diabetes surveillance and examining other important clinical and epidemiological questions.
Collapse
Affiliation(s)
- Hongmei Zhang
- The George Institute for Global Health, UNSW, Sydney, NSW, Australia
- Department of Endocrinology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
| | - Kris Rogers
- The George Institute for Global Health, UNSW, Sydney, NSW, Australia
- Graduate School of Health, University of Technology Sydney, Sydney, NSW, Australia
| | - Louisa Sukkar
- The George Institute for Global Health, UNSW, Sydney, NSW, Australia
- School of Public Health, University of Sydney, Sydney, Australia
| | - Min Jun
- The George Institute for Global Health, UNSW, Sydney, NSW, Australia
- Faculty of Medicine, University of New South Wales, Sydney, Australia
| | - Amy Kang
- The George Institute for Global Health, UNSW, Sydney, NSW, Australia
- Faculty of Medicine, University of New South Wales, Sydney, Australia
| | - Tamara Young
- The George Institute for Global Health, UNSW, Sydney, NSW, Australia
- Faculty of Medicine, University of New South Wales, Sydney, Australia
| | - Anna Campain
- The George Institute for Global Health, UNSW, Sydney, NSW, Australia
- Faculty of Medicine, University of New South Wales, Sydney, Australia
| | - Alan Cass
- Menzies School of Health Research, Charles Darwin University, Darwin, NT, Australia
| | - Clara K Chow
- The George Institute for Global Health, UNSW, Sydney, NSW, Australia
- Westmead Applied Research Centre, Faculty of Medicine and Health, University of Sydney, Sydney, Australia
- Department of Cardiology, Westmead Hospital, Sydney, Australia
| | - Elizabeth Comino
- Centre for Primary Health Care and Equity, University of New South Wales, Sydney, NSW, Australia
| | - Celine Foote
- The George Institute for Global Health, UNSW, Sydney, NSW, Australia
- Concord Repatriation General Hospital, Sydney, NSW, Australia
| | - Martin Gallagher
- The George Institute for Global Health, UNSW, Sydney, NSW, Australia
- Faculty of Medicine, University of New South Wales, Sydney, Australia
- Concord Repatriation General Hospital, Sydney, NSW, Australia
- Sydney Medical School, University of Sydney, Sydney, Australia
| | - John Knight
- The George Institute for Global Health, UNSW, Sydney, NSW, Australia
- Faculty of Medicine, University of New South Wales, Sydney, Australia
| | - Bette Liu
- School of Public Health and Community Medicine, University of New South Wales, Sydney, NSW, Australia
| | - Thomas Lung
- The George Institute for Global Health, UNSW, Sydney, NSW, Australia
- Faculty of Medicine, University of New South Wales, Sydney, Australia
| | | | - David Peiris
- The George Institute for Global Health, UNSW, Sydney, NSW, Australia
- Faculty of Medicine, University of New South Wales, Sydney, Australia
| | - Carol Pollock
- Renal Division, Kolling Institute for Medical Research, Sydney, Australia
- University of Sydney, Sydney, Australia
| | - David Sullivan
- Sydney Medical School, University of Sydney, Sydney, Australia
- Department of Chemical Pathology, Royal Prince Alfred Hospital, Sydney, Australia
| | - Germaine Wong
- School of Public Health, University of Sydney, Sydney, Australia
- Centre for Transplant and Renal Research, Westmead Hospital, Sydney, Australia
| | - Sophia Zoungas
- The George Institute for Global Health, UNSW, Sydney, NSW, Australia
- School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia
| | - Meg Jardine
- The George Institute for Global Health, UNSW, Sydney, NSW, Australia
- Faculty of Medicine, University of New South Wales, Sydney, Australia
- Concord Repatriation General Hospital, Sydney, NSW, Australia
| | - Carinna Hockham
- The George Institute for Global Health, UNSW, Sydney, NSW, Australia
- Faculty of Medicine, University of New South Wales, Sydney, Australia
- Corresponding author at: The George Institute for Global Health, 1 King Street, Newtown, NSW 2042, Australia.
| | | |
Collapse
|
4
|
Xie Y, Baker J, Young T, Jun M, Sukkar L, Campain A, Kang A, Cass A, Hu J, Peiris D, Pollock C, Wong G, Zoungas S, Rogers K, Jardine M, Hockham C. Therapy Escalation Following an Elevated HbA 1c in Adults Aged 45 Years and Older Living With Diabetes in Australia: A Real-World Observational Analysis. Diabetes Care 2020; 43:e185-e187. [PMID: 32928956 DOI: 10.2337/dc20-0269] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/06/2020] [Accepted: 08/07/2020] [Indexed: 02/03/2023]
Affiliation(s)
- Ying Xie
- The Second Affiliated Hospital of Soochow University, Suzhou, China.,The George Institute for Global Health, Sydney, New South Wales, Australia
| | - Jannah Baker
- The George Institute for Global Health, Sydney, New South Wales, Australia
| | - Tamara Young
- The George Institute for Global Health, Sydney, New South Wales, Australia.,Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia
| | - Min Jun
- The George Institute for Global Health, Sydney, New South Wales, Australia.,Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia
| | - Louisa Sukkar
- The George Institute for Global Health, Sydney, New South Wales, Australia.,School of Public Health, University of Sydney, Sydney, New South Wales, Australia
| | - Anna Campain
- The George Institute for Global Health, Sydney, New South Wales, Australia.,Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia
| | - Amy Kang
- The George Institute for Global Health, Sydney, New South Wales, Australia.,Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia
| | - Alan Cass
- Menzies School of Health Research, Charles Darwin University, Darwin, Northern Territory, Australia
| | - Ji Hu
- The Second Affiliated Hospital of Soochow University, Suzhou, China
| | - David Peiris
- The George Institute for Global Health, Sydney, New South Wales, Australia.,Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia
| | - Carol Pollock
- Renal Division, Kolling Institute for Medical Research, Sydney, New South Wales, Australia.,University of Sydney, Sydney, New South Wales, Australia
| | - Germaine Wong
- School of Public Health, University of Sydney, Sydney, New South Wales, Australia.,Centre for Transplant and Renal Research, Westmead Hospital, Sydney, New South Wales, Australia
| | - Sophia Zoungas
- The George Institute for Global Health, Sydney, New South Wales, Australia.,School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia
| | - Kris Rogers
- The George Institute for Global Health, Sydney, New South Wales, Australia.,Graduate School of Health, University of Technology Sydney, Sydney, New South Wales, Australia
| | - Meg Jardine
- The George Institute for Global Health, Sydney, New South Wales, Australia.,Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia.,Concord Repatriation General Hospital, Sydney, New South Wales, Australia
| | | | | |
Collapse
|
5
|
Kang A, Sukkar L, Hockham C, Jun M, Young T, Scaria A, Foote C, Neuen BL, Cass A, Pollock C, Comino E, Lung T, Pecoits-Filho R, Rogers K, Jardine MJ. Risk Factors for Incident Kidney Disease in Older Adults: an Australian Prospective Population-Based Study. Intern Med J 2020; 52:808-817. [PMID: 33012112 DOI: 10.1111/imj.15074] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2020] [Revised: 09/23/2020] [Accepted: 09/30/2020] [Indexed: 11/28/2022]
Abstract
BACKGROUND We aimed to determine risk factors for incident CKD in a large population-based cohort. METHODS This prospective opt-in population-based cohort study is based on the 45 and Up Study, where New South Wales residents aged ≥45 years were randomly sampled from the Services Australia enrolment database and agreed to complete the 45 and Up Study baseline questionnaire and have their responses linked to their health data in routinely-collected databases. The primary outcome was the development of incident CKD, defined as eGFR<60ml/min/1.73m2 . CKD incidence was calculated using Poisson regression. Risk factors for incident CKD were assessed using Cox regression in multivariable models. RESULTS In 39,574 participants who did not have CKD at enrolment, independent factors associated with developing CKD included: older age, regional residence (HR 1.38 [1.27-1.50] for outer regional versus major city), smoking (1.13 [1.00-1.27] for current smoker versus non-smoker), obesity (1.25 [1.16-1.35] for obese versus normal body mass index), diabetes mellitus (1.41 [1.33-1.50]), hypertension (1.53 [1.44-1.62]), coronary heart disease (1.13 [1.07-1.20]), depression/anxiety (1.16 [1.09-1.24]), and cancer (1.29 [1.20-1.39]). Migrants were less likely to develop CKD compared with people born in Australia (0.88 [0.83-0.94]). Gender, partner status and socioeconomic factors were not independently associated with developing CKD. CONCLUSIONS This large population-based study found multiple modifiable and non-modifiable factors were independently associated with developing CKD. In the Australian setting, the risk of CKD was higher with regional residence. Differences according to socioeconomic status were predominantly explained by age, comorbidities and harmful health-related behaviours This article is protected by copyright. All rights reserved.
Collapse
Affiliation(s)
- Amy Kang
- The George Institute for Global Health, UNSW Sydney, Australia
| | - Louisa Sukkar
- The George Institute for Global Health, UNSW Sydney, Australia.,Faculty of Medicine and Health, The University of Sydney, Sydney, Australia
| | - Carinna Hockham
- The George Institute for Global Health, UNSW Sydney, Australia
| | - Min Jun
- The George Institute for Global Health, UNSW Sydney, Australia
| | - Tamara Young
- The George Institute for Global Health, UNSW Sydney, Australia
| | - Anish Scaria
- The George Institute for Global Health, UNSW Sydney, Australia
| | - Celine Foote
- The George Institute for Global Health, UNSW Sydney, Australia.,Concord Hospital, Concord, New South Wales, Australia
| | - Brendon L Neuen
- The George Institute for Global Health, UNSW Sydney, Australia
| | - Alan Cass
- Menzies School of Health Research, Charles Darwin University, Darwin, Northern Territory, Australia
| | - Carol Pollock
- Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.,Royal North Shore Hospital, St Leonards, New South Wales, Australia
| | | | - Thomas Lung
- The George Institute for Global Health, UNSW Sydney, Australia.,Faculty of Medicine and Health, The University of Sydney, Sydney, Australia
| | - Roberto Pecoits-Filho
- School of Medicine, Pontificia Universidade Catolica do Parana, Brazil.,Arbor Research Collaborative for Health, USA
| | - Kris Rogers
- The George Institute for Global Health, UNSW Sydney, Australia.,Graduate School of Health, University of Technology, Sydney, Australia
| | - Meg J Jardine
- The George Institute for Global Health, UNSW Sydney, Australia.,Concord Hospital, Concord, New South Wales, Australia.,NHMRC Clinical Trials Centre, University of Sydney
| | | |
Collapse
|
6
|
Sukkar L, Kang A, Hockham C, Young T, Jun M, Foote C, Pecoits-Filho R, Neuen B, Rogers K, Pollock C, Cass A, Sullivan D, Wong G, Knight J, Peiris D, Gallagher M, Jardine M. Incidence and Associations of Chronic Kidney Disease in Community Participants With Diabetes: A 5-Year Prospective Analysis of the EXTEND45 Study. Diabetes Care 2020; 43:982-990. [PMID: 32161053 PMCID: PMC7809711 DOI: 10.2337/dc19-1803] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/09/2019] [Accepted: 01/31/2020] [Indexed: 02/03/2023]
Abstract
OBJECTIVE To determine the incidence of and factors associated with an estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2 in people with diabetes. RESEARCH DESIGN AND METHODS We identified people with diabetes in the EXamining ouTcomEs in chroNic Disease in the 45 and Up Study (EXTEND45), a population-based cohort study (2006-2014) that linked the Sax Institute's 45 and Up Study cohort to community laboratory and administrative data in New South Wales, Australia. The study outcome was the first eGFR measurement <60 mL/min/1.73 m2 recorded during the follow-up period. Participants with eGFR < 60 mL/min/1.73 m2 at baseline were excluded. We used Poisson regression to estimate the incidence of eGFR <60 mL/min/1.73 m2 and multivariable Cox regression to examine factors associated with the study outcome. RESULTS Of 9,313 participants with diabetes, 2,106 (22.6%) developed incident eGFR <60 mL/min/1.73 m2 over a median follow-up time of 5.7 years (interquartile range, 3.0-5.9 years). The eGFR <60 mL/min/1.73 m2 incidence rate per 100 person-years was 6.0 (95% CI 5.7-6.3) overall, 1.5 (1.3-1.9) in participants aged 45-54 years, 3.7 (3.4-4.0) for 55-64 year olds, 7.6 (7.1-8.1) for 65-74 year olds, 15.0 (13.0-16.0) for 75-84 year olds, and 26.0 (22.0-32.0) for those aged 85 years and over. In a fully adjusted multivariable model incidence was independently associated with age (hazard ratio 1.23 per 5-year increase; 95% CI 1.19-1.26), geography (outer regional and remote versus major city: 1.36; 1.17-1.58), obesity (obese class III versus normal: 1.44; 1.16-1.80), and the presence of hypertension (1.52; 1.33-1.73), coronary heart disease (1.13; 1.02-1.24), cancer (1.30; 1.14-1.50), and depression/anxiety (1.14; 1.01-1.27). CONCLUSIONS In participants with diabetes, the incidence of an eGFR <60 mL/min/1.73 m2 was high. Older age, remoteness of residence, and the presence of various comorbid conditions were associated with higher incidence.
Collapse
Affiliation(s)
- Louisa Sukkar
- The George Institute for Global Health, University of New South Wales, Sydney, Australia .,Faculty of Medicine and Health, University of Sydney, Sydney, Australia
| | - Amy Kang
- The George Institute for Global Health, University of New South Wales, Sydney, Australia
| | - Carinna Hockham
- The George Institute for Global Health, University of New South Wales, Sydney, Australia
| | - Tamara Young
- The George Institute for Global Health, University of New South Wales, Sydney, Australia
| | - Min Jun
- The George Institute for Global Health, University of New South Wales, Sydney, Australia
| | - Celine Foote
- The George Institute for Global Health, University of New South Wales, Sydney, Australia.,Concord Repatriation General Hospital, Concord West, New South Wales, Australia
| | | | - Brendon Neuen
- The George Institute for Global Health, University of New South Wales, Sydney, Australia
| | - Kris Rogers
- The George Institute for Global Health, University of New South Wales, Sydney, Australia.,Graduate School of Health, University of Technology Sydney, Sydney, New South Wales, Australia
| | - Carol Pollock
- Kolling Institute for Medical Research, St. Leonards, New South Wales, Australia
| | - Alan Cass
- Menzies School of Health Research, Casuarina, Northern Territory, Australia
| | - David Sullivan
- National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia
| | - Germaine Wong
- Centre for Kidney Research, University of Sydney, Sydney, New South Wales, Australia
| | - John Knight
- The George Institute for Global Health, University of New South Wales, Sydney, Australia
| | - David Peiris
- The George Institute for Global Health, University of New South Wales, Sydney, Australia
| | - Martin Gallagher
- The George Institute for Global Health, University of New South Wales, Sydney, Australia.,Concord Repatriation General Hospital, Concord West, New South Wales, Australia
| | | | | |
Collapse
|
7
|
Foote C, Hockham C, Sukkar L, Campain A, Kang A, Young T, Cass A, Chow CK, Comino E, Gallagher M, Jan S, Knight J, Liu B, McNamara M, Peiris D, Pollock C, Sullivan D, Wong G, Zoungas S, Rogers K, Jun M, Jardine M. EXamining ouTcomEs in chroNic Disease in the 45 and Up Study (the EXTEND45 Study): Protocol for an Australian Linked Cohort Study. JMIR Res Protoc 2020; 9:e15646. [PMID: 32285803 PMCID: PMC7189250 DOI: 10.2196/15646] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2019] [Revised: 12/06/2019] [Accepted: 01/07/2020] [Indexed: 01/04/2023] Open
Abstract
Background Chronic kidney disease (CKD) and diabetes are the major causes of death and disability worldwide. They are associated with high health service utilization persisting over many years. Their slow progression and wide clinical variation make them eminently suitable for study in population-based cohorts. However, current understanding of their prevalence, incidence, and progression is largely based on studies conducted in clinical populations. Objective This study aims to establish a novel link between an existing population-based cohort (the 45 and Up Study) and routinely collected laboratory and administrative data to facilitate research across the full disease spectrum of CKD and diabetes. Methods In the EXTEND45 Study (EXamining OuTcomEs in chroNic Disease in the 45 and Up Study), baseline questionnaire responses of over 260,000 participants of the 45 and Up Study aged ≥45 years living in New South Wales (NSW), collected between January 2006 and December 2009, are linked to data from laboratory service providers as well as national- and state-based administrative datasets via probabilistic linkage. Routinely collected data were obtained for participants who could be linked between January 2005 and July 2013. Laboratory data will enable the identification of early cases of chronic disease and the assessment of clinically relevant biochemical targets during the disease course. Health administrative datasets will allow for the examination of health service use, pharmacological management, and clinical outcomes. Results The study received ethics approval from the NSW Population and Health Services Research Ethics Committee in February 2014. Data linkage for 267,153 of the 45 and Up Study participants was completed in June 2016, with congruent linkage achieved for 265,086 (99.23%) individuals. To date, the CKD and diabetes cohorts have been identified (published elsewhere), and a diverse portfolio of research projects relating to disease burden, risk factors, health outcomes, and health service utilization is in development. Conclusions The EXTEND45 Study represents an unparalleled opportunity to perform extensive research into diseases of considerable public health and clinical importance. Strengths include the population-based nature of the cohort and the availability of longitudinal information on the complete disease pathway for affected individuals. International Registered Report Identifier (IRRID) RR1-10.2196/15646
Collapse
Affiliation(s)
- Celine Foote
- The George Institute for Global Health, Sydney, Australia.,Concord Repatriation General Hospital, Sydney, Australia
| | - Carinna Hockham
- The George Institute for Global Health, Sydney, Australia.,Faculty of Medicine, University of New South Wales, Sydney, Australia
| | - Louisa Sukkar
- The George Institute for Global Health, Sydney, Australia.,School of Public Health, University of Sydney, Sydney, Australia
| | - Anna Campain
- The George Institute for Global Health, Sydney, Australia.,Faculty of Medicine, University of New South Wales, Sydney, Australia
| | - Amy Kang
- The George Institute for Global Health, Sydney, Australia.,Faculty of Medicine, University of New South Wales, Sydney, Australia
| | - Tamara Young
- The George Institute for Global Health, Sydney, Australia.,Faculty of Medicine, University of New South Wales, Sydney, Australia
| | - Alan Cass
- Menzies School of Health Research, Charles Darwin University, Darwin, Australia
| | - Clara K Chow
- The George Institute for Global Health, Sydney, Australia.,Westmead Applied Research Centre, Faculty of Medicine and Health, University of Sydney, Sydney, Australia.,Department of Cardiology, Westmead Hospital, Sydney, Australia
| | - Elizabeth Comino
- Centre for Primary Health Care and Equity, University of New South Wales, Sydney, Australia
| | - Martin Gallagher
- The George Institute for Global Health, Sydney, Australia.,Concord Repatriation General Hospital, Sydney, Australia.,Faculty of Medicine, University of New South Wales, Sydney, Australia.,Sydney Medical School, University of Sydney, Sydney, Australia
| | - Stephen Jan
- The George Institute for Global Health, Sydney, Australia.,Faculty of Medicine, University of New South Wales, Sydney, Australia.,Sydney Medical School, University of Sydney, Sydney, Australia
| | - John Knight
- The George Institute for Global Health, Sydney, Australia.,Faculty of Medicine, University of New South Wales, Sydney, Australia
| | - Bette Liu
- School of Public Health and Community Medicine, University of New South Wales, Sydney, Australia
| | | | - David Peiris
- The George Institute for Global Health, Sydney, Australia.,Faculty of Medicine, University of New South Wales, Sydney, Australia
| | - Carol Pollock
- Renal Division, Kolling Institute for Medical Research, Sydney, Australia.,University of Sydney, Sydney, Australia
| | - David Sullivan
- Sydney Medical School, University of Sydney, Sydney, Australia.,Department of Chemical Pathology, Royal Prince Alfred Hospital, Sydney, Australia
| | - Germaine Wong
- School of Public Health, University of Sydney, Sydney, Australia.,Centre for Transplant and Renal Research, Westmead Hospital, Sydney, Australia
| | - Sophia Zoungas
- The George Institute for Global Health, Sydney, Australia.,School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia
| | - Kris Rogers
- The George Institute for Global Health, Sydney, Australia.,Graduate School of Health, University of Technology Sydney, Sydney, Australia
| | - Min Jun
- The George Institute for Global Health, Sydney, Australia.,Faculty of Medicine, University of New South Wales, Sydney, Australia
| | - Meg Jardine
- The George Institute for Global Health, Sydney, Australia.,Concord Repatriation General Hospital, Sydney, Australia
| |
Collapse
|
8
|
Sukkar L, Young T, Jardine MJ. How Do the Recent Major Randomized Controlled Trials Inform Best Use of the Novel Glucose-Lowering Agents? Kidney Blood Press Res 2020; 45:823-836. [DOI: 10.1159/000511214] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2020] [Accepted: 08/30/2020] [Indexed: 11/19/2022] Open
Abstract
<b><i>Background:</i></b> Type 2 diabetes mellitus (T2DM) is frequently associated with the development of cardiovascular disease and chronic kidney disease (CKD). Some newer glucose-lowering agents confer both cardiac and kidney benefits, as supported by robust data from recent high-quality randomized controlled trials. The decision-making process when selecting glucose-lowering medications for T2DM now extends beyond glycaemia and metabolic effects, and towards additional benefits such as prevention of other complications. <b><i>Summary:</i></b> We review the evidence for efficacy in 3 new classes of medication for T2DM and additionally discuss relevant safety issues when considering optimal agents. <b><i>Key Messages:</i></b> Clinicians have multiple efficacy and safety factors to consider when selecting agents for glucose lowering in T2DM, and this should help direct individualized selection of pharmacotherapy for patients. New medications offer an opportunity to prevent cardiac and renal complications in people with T2DM.
Collapse
|
9
|
Sukkar L, Talbot B, Jun M, Dempsey E, Walker R, Hooi L, Cass A, Jardine M, Gallagher M. Protocol for the Study of Heart and Renal Protection-Extended Review: Additional 5-Year Follow-up of the Australian, New Zealand, and Malaysian SHARP Cohort. Can J Kidney Health Dis 2019; 6:2054358119879896. [PMID: 31662874 PMCID: PMC6794650 DOI: 10.1177/2054358119879896] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2019] [Accepted: 08/11/2019] [Indexed: 11/17/2022] Open
Abstract
Background: There are limited studies on the effects of statins on outcomes in the
moderate chronic kidney disease (CKD) population and their trajectory to
end-stage kidney disease. Objective: To examine the long-term effects of lipid-lowering therapy on all-cause
mortality, cardiovascular morbidity, CKD progression, and socioeconomic
well-being in Australian, New Zealand, and Malaysian SHARP (Study of Heart
and Renal Protection) trial participants—a randomized controlled trial of a
combination of simvastatin and ezetimibe, compared with placebo, for the
reduction of cardiovascular events in moderate to severe CKD. Design: Protocol for an extended prospective observational follow-up. Setting: Australian, New Zealand, and Malaysian participating centers in patients with
advanced CKD. Patients: All SHARP trial participants alive at the final study visit. Measurements: Primary outcomes were measured by participant self-report and verified by
hospital administrative data. In addition, secondary outcomes were measured
using a validated study questionnaire of health-related quality of life, a
56-item economic survey. Methods: Participants were followed up with alternating face-to-face visits and
telephone calls on a 6-monthly basis until 5 years following their final
SHARP Study visit. In addition, there were 6-monthly follow-up telephone
calls in between these visits. Data linkage to health registries in
Australia, New Zealand, and Malaysia was also performed. Results: The SHARP-Extended Review (SHARP-ER) cohort comprised 1136 SHARP participants
with a median of 4.6 years of follow-up. Compared with all SHARP
participants who originally participated in the Australian, New Zealand, and
Malaysian regions, the SHARP-ER participants were younger (57.2 [48.3-66.4]
vs 60.5 [50.3-70.7] years) with a lower proportion of men (61.5% vs 62.8%).
There were a lower proportion of participants with hypertension (83.7% vs
85.0%) and diabetes (20.0% vs 23.5%). Limitations: As a long-term follow-up study, the surviving cohort of SHARP-ER is a
selected group of the original study participants, which may limit the
generalizability of the findings. Conclusion: The SHARP-ER study will contribute important evidence on the long-term
outcomes of cholesterol-lowering therapy in patients with advanced CKD with
a total of 10 years of follow-up. Novel analyses of the socioeconomic impact
of CKD over time will guide resource allocation. Trial Registration: The SHARP trial was registered at ClinicalTrials.gov NCT00125593 and ISRCTN
54137607.
Collapse
Affiliation(s)
- Louisa Sukkar
- The George Institute for Global Health, Newtown, Australia.,Faculty of Medicine and Health, The University of Sydney, NSW, Australia
| | - Ben Talbot
- The George Institute for Global Health, Newtown, Australia
| | - Min Jun
- The George Institute for Global Health, Newtown, Australia
| | - Erika Dempsey
- The George Institute for Global Health, Newtown, Australia
| | - Robert Walker
- Dunedin School of Medicine, University of Otago, Dunedin, New Zealand
| | - Lai Hooi
- Hospital Sultanah Aminah, Johor Bahru, Malaysia
| | - Alan Cass
- Menzies School of Health Research, Casuarina, NT, Australia
| | - Meg Jardine
- The George Institute for Global Health, Newtown, Australia.,Faculty of Medicine and Health, The University of Sydney, NSW, Australia
| | - Martin Gallagher
- The George Institute for Global Health, Newtown, Australia.,Faculty of Medicine and Health, The University of Sydney, NSW, Australia
| |
Collapse
|
10
|
YOUNG T, Hockham C, Sukkar L, Kang A, Jun M, Baker J, Rogers K, Cass A, Jardine M. SAT-288 Trends in pharmacotherapy for diabetes in a large Australian cohort: results from the EXTEND45 study. Kidney Int Rep 2019. [DOI: 10.1016/j.ekir.2019.05.326] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
11
|
HOCKHAM C, Kang A, Young T, Sukkar L, Jun M, Rogers K, Baker J, Cass A, Jardine M. SAT-241 SMALL AREA-LEVEL VARIATION IN CHRONIC KIDNEY DISEASE PREVALENCE AND INCIDENCE IN NEW SOUTH WALES. Kidney Int Rep 2019. [DOI: 10.1016/j.ekir.2019.05.277] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
12
|
Quinto LR, Sukkar L, Gallagher M. Effectiveness of corticosteroid compared with non‐corticosteroid therapy for the treatment of drug‐induced acute interstitial nephritis: a systematic review. Intern Med J 2019; 49:562-569. [DOI: 10.1111/imj.14081] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2018] [Revised: 07/30/2018] [Accepted: 08/06/2018] [Indexed: 11/29/2022]
Affiliation(s)
- Lena R. Quinto
- Sydney Medical SchoolUniversity of Sydney Sydney New South Wales Australia
| | - Louisa Sukkar
- Sydney Medical SchoolUniversity of Sydney Sydney New South Wales Australia
- The George Institute for Global HealthUNSW Sydney New South Wales Australia
- Sydney School of Public HealthThe University of Sydney Sydney New South Wales Australia
| | - Martin Gallagher
- Sydney Medical SchoolUniversity of Sydney Sydney New South Wales Australia
- The George Institute for Global HealthUNSW Sydney New South Wales Australia
| |
Collapse
|
13
|
Makris A, Thornton C, Tooher J, Brieger G, Ogle R, Sukkar L, Mannan H, Robertson A, Lee G, Kumar R, Douglas I, Hennessy A. 301. Effect of non-steroidal anti-inflammatory drugs (NSAIDs) on post-operative analgesia after ceaserean section: Randomised controlled trial. Pregnancy Hypertens 2018. [DOI: 10.1016/j.preghy.2018.08.123] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
14
|
Wong MG, Ninomiya T, Liyanage T, Sukkar L, Hirakawa Y, Wang Y, Wyld MLR, Morton RL, Chadban S, Howard K, Jardine MJ. Physical component quality of life reflects the impact of time and moderate chronic kidney disease, unlike SF-6D utility and mental component SF-36 quality of life: An AusDiab analysis. Nephrology (Carlton) 2018; 24:605-614. [PMID: 30039893 DOI: 10.1111/nep.13445] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/09/2018] [Indexed: 01/22/2023]
Abstract
AIM Assessing the impact of interventions on the patient experience requires measures that are plausibly responsive to change. In a community cohort of people with and without chronic kidney disease (CKD) markers at baseline, we aimed to evaluate change in commonly used measures of quality of life (QOL) over the passage of 5 years. METHODS Included were 6400 participants in the Australian Diabetes, Obesity and Lifestyle (AusDiab) surveys with baseline and 5-year CKD and QOL measures. Changes in SF-6D utility, and the Medical Outcomes Study 36-Item Short Form (SF-36) physical (PCS) and mental (MCS) component summary scores, were evaluated with regression analyses according to the baseline presence of reduced estimated glomerular filtration rate (eGFR) (CKD-Epidemiology Collaboration eGFR ≤60 m/min per 1.73 m2 ) or albuminuria (urine albumin:creatinine ratio ≥3.4 mg/mmol). RESULTS At baseline, eGFR was reduced in 2.4% of participants and 5.1% had albuminuria. Participants with reduced eGFR had a lower SF-6D and PCS, and those with albuminuria a lower PCS, compared with those without, but the differences were explained by known confounders. MCS scores were not affected by the presence of reduced eGFR or albuminuria. Over 5 years all groups exhibited stable SF-6D and MCS scores but declining unadjusted PCS scores. PCS decline was greater for those with reduced eGFR, and remained significant after adjustment (-2.7 (-4.1 to -1.3) vs. -0.8 (-1.1 to -0.6, P < 0.01). Analyses according to CKD stages were essentially unchanged. CONCLUSION Utility and mental QOL appears stable over 5 years, unaffected by time or markers of CKD health. Physical QOL appeared to deteriorate with time, especially for those with CKD, making it a more likely candidate assessment measure for intervention and health service evaluations.
Collapse
Affiliation(s)
- Muh G Wong
- The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia.,Department of Renal Medicine, Royal North Shore Hospital, University of Sydney, Sydney, New South Wales, Australia
| | - Toshiharu Ninomiya
- The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia.,Department of Epidemiology and Public Health, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - Thaminda Liyanage
- The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia.,Armadale Kelmscott Memorial Hospital, South Metropolitan Health Service, Western Australia, Australia
| | - Louisa Sukkar
- The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia.,Sydney School of Public Health, University of Sydney, Sydney, New South Wales, Australia
| | - Yoichiro Hirakawa
- The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia
| | - Ying Wang
- The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia
| | - Melanie L R Wyld
- Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia.,Department of Renal Medicine, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia
| | - Rachel L Morton
- NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia
| | - Steven Chadban
- Department of Renal Medicine, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia
| | - Kirsten Howard
- NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia
| | - Meg J Jardine
- The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia.,Department of Renal Medicine, Concord Repatriation General Hospital, Sydney, New South Wales, Australia
| |
Collapse
|
15
|
Wang AY, Sherrington C, Toyama T, Gallagher MP, Cass A, Hirakawa Y, Li Q, Sukkar L, Snelling P, Jardine MJ. Muscle strength, mobility, quality of life and falls in patients on maintenance haemodialysis: A prospective study. Nephrology (Carlton) 2017; 22:220-227. [DOI: 10.1111/nep.12749] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2015] [Revised: 01/20/2016] [Accepted: 02/11/2016] [Indexed: 12/01/2022]
Affiliation(s)
- Amanda Y Wang
- The George Institute for Global Health, Sydney Medical School; University of Sydney; Sydney New South Wales Australia
| | - Catherine Sherrington
- The George Institute for Global Health, Sydney Medical School; University of Sydney; Sydney New South Wales Australia
| | - Tadashi Toyama
- The George Institute for Global Health, Sydney Medical School; University of Sydney; Sydney New South Wales Australia
| | - Martin P Gallagher
- The George Institute for Global Health, Sydney Medical School; University of Sydney; Sydney New South Wales Australia
- Sydney Medical School; University of Sydney; Sydney New South Wales Australia
- Concord Repatriation General Hospital; Sydney New South Wales Australia
| | - Alan Cass
- The George Institute for Global Health, Sydney Medical School; University of Sydney; Sydney New South Wales Australia
- Menzies School of Health Research; Darwin Northern Territory Australia
| | - Yochiro Hirakawa
- The George Institute for Global Health, Sydney Medical School; University of Sydney; Sydney New South Wales Australia
| | - Qiang Li
- The George Institute for Global Health, Sydney Medical School; University of Sydney; Sydney New South Wales Australia
| | - Louisa Sukkar
- The George Institute for Global Health, Sydney Medical School; University of Sydney; Sydney New South Wales Australia
| | - Paul Snelling
- Royal Prince Alfred Hospital; Sydney New South Wales Australia
| | - Meg J Jardine
- The George Institute for Global Health, Sydney Medical School; University of Sydney; Sydney New South Wales Australia
- Concord Repatriation General Hospital; Sydney New South Wales Australia
| |
Collapse
|
16
|
Sukkar L, Hong D, Wong MG, Badve SV, Rogers K, Perkovic V, Walsh M, Yu X, Hillis GS, Gallagher M, Jardine M. Effects of ischaemic conditioning on major clinical outcomes in people undergoing invasive procedures: systematic review and meta-analysis. BMJ 2016; 355:i5599. [PMID: 27821641 PMCID: PMC5098417 DOI: 10.1136/bmj.i5599] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
OBJECTIVE To summarise the benefits and harms of ischaemic conditioning on major clinical outcomes in various settings. DESIGN Systematic review and meta-analysis. DATA SOURCES Medline, Embase, Cochrane databases, and International Clinical Trials Registry platform from inception through October 2015. STUDY SELECTION All randomised controlled comparisons of the effect of ischaemic conditioning on clinical outcomes were included. DATA EXTRACTION Two authors independently extracted data from individual reports. Reports of multiple intervention arms were treated as separate trials. Random effects models were used to calculate summary estimates for all cause mortality and other pre-specified clinical outcomes. All cause mortality and secondary outcomes with P<0.1 were examined for study quality by using the GRADE assessment tool, the effect of pre-specified characteristics by using meta-regression and Cochran C test, and trial sequential analysis by using the Copenhagen Trial Unit method. RESULTS 85 reports of 89 randomised comparisons were identified, with a median 80 (interquartile range 60-149) participants and median 1 (range 1 day-72 months) month intended duration. Ischaemic conditioning had no effect on all cause mortality (68 comparisons; 424 events; 11 619 participants; risk ratio 0.96, 95% confidence interval 0.80 to 1.16; P=0.68; moderate quality evidence) regardless of the clinical setting in which it was used or the particular intervention related characteristics. Ischaemic conditioning may reduce the rates of some secondary outcomes including stroke (18 trials; 5995 participants; 149 events; risk ratio 0.72, 0.52 to 1.00; P=0.048; very low quality evidence) and acute kidney injury (36 trials; 8493 participants; 1443 events; risk ratio 0.83, 0.71 to 0.97; P=0.02; low quality evidence), although the benefits seem to be confined to non-surgical settings and to mild episodes of acute kidney injury only. CONCLUSIONS Ischaemic conditioning has no overall effect on the risk of death. Possible effects on stroke and acute kidney injury are uncertain given methodological concerns and low event rates. Adoption of ischaemic conditioning cannot be recommended for routine use unless further high quality and well powered evidence shows benefit.
Collapse
Affiliation(s)
- Louisa Sukkar
- The George Institute for Global Health, University of Sydney, Sydney, NSW 2050, Australia
- Concord Clinical School, University of Sydney, Sydney, Australia
| | - Daqing Hong
- The George Institute for Global Health, University of Sydney, Sydney, NSW 2050, Australia
- Division of Nephrology, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, Chengdu, China
| | - Muh Geot Wong
- The George Institute for Global Health, University of Sydney, Sydney, NSW 2050, Australia
| | - Sunil V Badve
- The George Institute for Global Health, University of Sydney, Sydney, NSW 2050, Australia
- St George Hospital, Kogarah, NSW, Australia
| | - Kris Rogers
- The George Institute for Global Health, University of Sydney, Sydney, NSW 2050, Australia
| | - Vlado Perkovic
- The George Institute for Global Health, University of Sydney, Sydney, NSW 2050, Australia
| | - Michael Walsh
- Departments of Medicine, Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Canada
- Population Health Research Institute, Hamilton, ON, Canada
| | - Xueqing Yu
- Sun Yat-Sen University, Guangdong Province, China
| | - Graham S Hillis
- The George Institute for Global Health, University of Sydney, Sydney, NSW 2050, Australia
- University of Western Australia, Crawley, WA, Australia
| | - Martin Gallagher
- The George Institute for Global Health, University of Sydney, Sydney, NSW 2050, Australia
- Concord Clinical School, University of Sydney, Sydney, Australia
| | - Meg Jardine
- The George Institute for Global Health, University of Sydney, Sydney, NSW 2050, Australia
- Concord Repatriation General Hospital, Sydney, Australia
| |
Collapse
|
17
|
Sukkar L, Hong D, Wong MG, Badve SV, Perkovic V, Yu X, Hillis GS, Gallagher M, Jardine M. MP221EFFECTS OF ISCHAEMIC CONDITIONING ON MAJOR CLINICAL OUTCOMES IN PEOPLE UNDERGOING INVASIVE PROCEDURES: A SYSTEMATIC REVIEW AND METAANALYSIS. Nephrol Dial Transplant 2016. [DOI: 10.1093/ndt/gfw187.27] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
18
|
Wang AY, Bellomo R, Cass A, Finfer S, Gattas D, Myburgh J, Chadban S, Hirakawa Y, Ninomiya T, Li Q, Lo S, Barzi F, Sukkar L, Jardine M, Gallagher MP. Health-related quality of life in survivors of acute kidney injury: The Prolonged Outcomes Study of the Randomized Evaluation of Normal versus Augmented Level Replacement Therapy study outcomes. Nephrology (Carlton) 2016; 20:492-8. [PMID: 25891297 DOI: 10.1111/nep.12488] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/09/2015] [Indexed: 11/30/2022]
Abstract
AIM While patients with chronic kidney disease have reduced health-related quality of life (HRQOL), long-term HRQOL of survivors of severe acute kidney injury (AKI) remains unclear. METHODS We analysed HRQOL from the Prolonged Outcomes Study of the Randomized Evaluation of Normal versus Augmented Level Replacement Therapy (POST-RENAL) study and compared findings with those from a general Australian adult population enrolled in the Australian Diabetes, Obesity and Lifestyle (AusDiab) study. We used a multivariate analysis adjusted for baseline characteristics along with sensitivity analysis using age and sex-matched case controls. RESULTS In the POST-RENAL study, 282 participants had HRQOL data collected using the SF-12 questionnaire. This was compared with 6330 participants from the AusDiab study. Unadjusted analyses showed that POST-RENAL participants had lower physical component scores (PCS, mean score 40.0 vs 49.8, P<0.0001) and lower mental component scores (MCS, mean score 49.8 vs 53.9, P<0.0001) than the AusDiab group. After age and sex matching, the difference in PCS and MCS remained statistically significant (P<0.0001). Advanced age, reduced renal function and albuminuria (all P ≤ 0.01) were all strongly associated with lower PCS values but not MCS values. After matching subsets of the cohorts on the basis of age, sex and renal function, PCS and MCS were lower in the POST-RENAL group (P<0.0001). CONCLUSION Survivors of severe AKI in the POST-RENAL study had lower physical and mental components of HRQOL compared with general population, even after adjustment for their reduced renal function. Increasing age and reduced renal function were associated with poorer physical QOL.
Collapse
Affiliation(s)
- Amanda Y Wang
- Renal and Metabolic Division, The George Institute for Global Health, Sydney, New South Wales, Australia.,Concord Clinical School, Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia
| | - Rinaldo Bellomo
- Renal and Metabolic Division, The George Institute for Global Health, Sydney, New South Wales, Australia.,Department of Intensive Care, Austin Hospital, Melbourne, Victoria, Australia
| | - Alan Cass
- Menzies School of Health Research, Darwin, Northern Territory, Australia
| | - Simon Finfer
- Renal and Metabolic Division, The George Institute for Global Health, Sydney, New South Wales, Australia.,Concord Clinical School, Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia
| | - David Gattas
- Renal and Metabolic Division, The George Institute for Global Health, Sydney, New South Wales, Australia.,Department of Renal Medicine, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia
| | - John Myburgh
- Renal and Metabolic Division, The George Institute for Global Health, Sydney, New South Wales, Australia.,St George and Sutherland Clinical School, The University of New South Wales, Sydney, New South Wales, Australia
| | - Steve Chadban
- Department of Renal Medicine, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.,Concord Clinical School, Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia
| | - Yoichiro Hirakawa
- Renal and Metabolic Division, The George Institute for Global Health, Sydney, New South Wales, Australia
| | - Toshiharu Ninomiya
- Renal and Metabolic Division, The George Institute for Global Health, Sydney, New South Wales, Australia
| | - Qiang Li
- Renal and Metabolic Division, The George Institute for Global Health, Sydney, New South Wales, Australia
| | - Serigne Lo
- Renal and Metabolic Division, The George Institute for Global Health, Sydney, New South Wales, Australia
| | - Federica Barzi
- Renal and Metabolic Division, The George Institute for Global Health, Sydney, New South Wales, Australia
| | - Louisa Sukkar
- Renal and Metabolic Division, The George Institute for Global Health, Sydney, New South Wales, Australia
| | - Meg Jardine
- Renal and Metabolic Division, The George Institute for Global Health, Sydney, New South Wales, Australia.,Concord Clinical School, Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia.,Department of Renal Medicine, Concord Repatriation General Hospital, Sydney, New South Wales, Australia
| | - Martin P Gallagher
- Renal and Metabolic Division, The George Institute for Global Health, Sydney, New South Wales, Australia.,Concord Clinical School, Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia.,Department of Renal Medicine, Concord Repatriation General Hospital, Sydney, New South Wales, Australia
| | | |
Collapse
|
19
|
Affiliation(s)
- Shikha Aggarwal
- Department of Renal Medicine and Transplantation; Royal Prince Alfred Hospital; Sydney New South Wales Australia
| | - Louisa Sukkar
- Department of Renal Medicine and Transplantation; Royal Prince Alfred Hospital; Sydney New South Wales Australia
| | - Lucy Wynter
- Department of Renal Medicine and Transplantation; Royal Prince Alfred Hospital; Sydney New South Wales Australia
| | - Kate Richards
- Department of Renal Medicine and Transplantation; Royal Prince Alfred Hospital; Sydney New South Wales Australia
| | - Jason Cheung
- Department of Renal Medicine and Transplantation; Royal Prince Alfred Hospital; Sydney New South Wales Australia
| | - Steve J Chadban
- Department of Renal Medicine and Transplantation; Royal Prince Alfred Hospital; Sydney New South Wales Australia
- Central Clinical School; Charles Perkins Centre; University of Sydney; Sydney New South Wales Australia
| |
Collapse
|